Treatments and Innovation
Molecular Diagnostic Lab
n Opened the laboratory for clinical testing on April 1, 2019,
with the TruSight Tumor 170, a next-generation sequencing
assay designed to cover 170 genes associated with common
solid tumors. This comprehensive, enrichment-based targeted
panel simultaneously analyzes DNA and RNA, covering a wide
range of genes and variant types, and provides laboratories
with a deep view into the genetics of cancer and allows for
microsatellite instability and rapid Epidermal Growth Factor
Receptor (EGFR) and BRAF analysis.
n Performed 165 genetic tests between April 2 and
August 26, 2019.
n Began performing viral quantification assays for Blood and
Marrow Transplant program on July 17, 2019, with a total of
105 tests performed as of August 26, 2019.